A correct clinical diagnosis in the early stage of Alzheimer disease (AD) is mandatory given the current available treatment with acetylcholine esterase inhibitors. Moreover, a early to preclinical diagnosis would allow to identify patients eligible for future diseasemodifying therapies.
INTRODUCTION
Few public health problems have captured the attention of the biomedical and lay communities as Alzheimer Disease has (AD). AD represents the most common neurodegenerative disease worldwide accounting for 60% to 70% of cases of progressive cognitive impairment in elderly patients (Cummings and Cole, 2002) A prompt and early diagnosis is mandatory for many reasons. Firstly, the introduction of acetylcholine esterase inhibitors as symptomatic treatment has highlighted the importance of diagnostic markers for AD (Cacabelos, 2008) . Such compounds will probably be most effective in the earlier stages of the disease, before neurodegeneration is too severe and widespread. The increased general knowledge of AD in the population and the awareness of the possibilities for drug treatment have also made patients seek medical advice early in the disease, when the characteristic clinical picture of dementia is rather subtle and barely noticeable. Secondly, in the last years it has been progressively characterised the preclinical phase of AD, and the term of Mild Cognitive Impairment (MCI) defines an heterogeneous population at higher risk to develop AD over time. An early identification of individuals with preclinical AD among MCI is crucial to prompt interventions.
Thus, the search of relevant biomarkers of AD in living patients has been an active part of clinical research for the last decade. As in other field of medicine, biomarkers have been developed to diagnose, prognose, and monitor disease progression. The assumption for such enterprise is that a biomarker provides at least an indirect link to the disease process or ideally directly relates to the primary mechanism of the disease.
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In the last few years, our group has focused the attention on the development of a peripheral biomarker in platelets, evaluating one of the key players of AD pathogenesis, namely the forms of Amyloid Precursor Protein (APP).
In this review, we summarise the usefulness of this biomarker for the diagnosis of AD since the early disease stages, both as single tool and in combination with neuroimaging markers . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 5
PLATELETS AS A LABORATORY TO STUDY ALZHEIMER DISEASE
The pathological hallmark of AD is the presence of senile plaques defined by the progressive deposition of beta amyloid in the parenchyma and cerebral microvasculature. Abeta originates by proteolytic processing from a larger precursor, the APP (Tanzi et al., 1987) , an integral transmembrane cell-surface protein present as numerous alternatively spliced isoforms derived from a single gene localized on human chromosome 21 (Selkoe et al., 1988 ).
This protein is expressed in central nervous system, but it is also ubiquitously expressed in several splice variants in peripheral tissues such as muscles cells, epithelial and circulating cells. Among the different peripheral cells expressing APP forms, platelets are particularly interesting since they show concentrations of the different forms equivalent to those found in brain (Bush et al., 1990 ).
Some differences between these two cellular populations are nevertheless present: the isoforms 695, lacking the Kunitz Proteinase Inhibitor (KPI) domain, is the most abundant in neuronal tissue, whereas its expression is nearly undetectable in platelets where the major isoforms is APP 770 (Tanzi et al., 1987) . The function of APP is yet unknown, but several hyphoteses have been put forward a possible physiological role in blood coagulation (Van Nostrand et al., 1990) of APP in platelets. It is known that APP containing KPI domain is highly homologous to Protein Nexin II and it inhibits the activity of the blood coagulation factors IXa, Xa, Xia (Van Nostrand et al., 1992) . It has been recently demonstrated that APP metabolism in platelets is regulated by thrombin and prostaglandine 2 (Smirnov et al., in press), but the relationship with AD is still to be defined. It can be hypothesized that APP metabolism might contribute to both the ). Evidences propose that platelets contain all the enzymatic machinery to produce alpha and beta-secretases metabolites, being an easily accessible source of human material where to study APP biochemistry and metabolism both in physiological or in pathological conditions (Chen et al., 1995) .
The appropriateness to use platelets finds its rationale in the numerous similar features of platelets and neurones: platelets store and release neurotransmitters, express appropriate neurotransmitter transporters and some neurone-related proteins such as NMDA receptors.
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PLATELET AMYLOID PRECURSOR PROTEIN AS A DIAGNOSTIC MARKER IN ALZHEIMER DISEASE
In 1996, the preliminary observation that patients affected by sporadic AD showed a significant alteration of the immunoreactivity of the APP forms in platelets prompted several studies to assess their diagnostic value (Di Luca et al., 1996; Rosenberg et al., 1997; Di Luca et al., 1998) .
The evaluation of APP forms was conducted by Western Blot analysis with monoclonal antibody 22C11 raised against the N-terminal domain of APP, therefore recognising the three APP forms with apparent molecular weight of 130, 110, and 106 kDa.
It has been clearly evident that AD patients had a reduced ratio between the upper (130 kDa) and the lower (106 to 110 kDa) immunoreactivity bands, when compared with healthy age-matched controls and patients with non-AD dementia (see Figure 2) .
In an extensive study performed on 85 patients with AD and 95 control subjects, the accuracy value of APP form ratio was further tested (Padovani et al., 2001b) . The control group included a subgroup of non demented subjects (n=52) who were either healthy individuals (normal volunteers, spouses or caregivers) or neurologic nondemented subjects, and a subgroup of patients affected by dementia non fulfilling AD criteria (n=43). In this study, both young (age<60 years old) and old (age>60 yearsold) nondemented controls were considered separately.
AD patients showed a mean APP form ratio of 0.35±0.18, whilst each control group had a mean ratio >0.83 (standard deviation range: 0.28-0.38).
A cut-off level of platelet APP form ratio lower or equal to 0.57 resulted in a sensitivity of 88.2% and a specificity of 89.4%, with an area under the curve (AUC) of the receiver operating curve (ROC) analysis of 0.945.
Reduction of the platelet APP ratio was found to be correlated with disease severity, measured either with Clinical Dementia Rating Scale or Mini-Mental Status Examination. The lower the APP form ratio score, the greater the disease severity, thus suggesting that this value varies according to the progression of clinical symptoms (Padovani et al., 2001b) . Mean APP form ratio of mild AD patients was 0.45±0.12, of moderate AD was 0.31±0.17, and of severe AD was 0.22±0.10, indicating that this peripheral biochemical parameter is modified early in the course of the disease as well (Padovani et al., 2001a) .
The test was demonstrated to be highly reproducible, with a interassay variability <10%. To confidentially measure the biomarker score, the blood drawing occurred while fasting, and the APP ratio for each subject was determined by averaging the values from three replications. The main limitation to perform the test is the likely interaction between APP metabolism and concurrent pharmacological treatment, i.e. cholinergic agents and antiplatelets drugs.
As it has been demonstrated the helpfulness of this biomarker in mild AD, when however the symptoms are already overt, a further step has been to consider the role of platelet APP ratio in very early and preclinical stages of AD (Padovani et al., 2002; Borroni et al., 2004) . To this aim, subjects with MCI were enrolled, and were followed up periodically for 2 years, and the progression to dementia was evaluated (Borroni et al., 2003) . Interestingly, MCI individuals who progressed to AD showed a significant decrease of baseline platelet APP forms ratio values (mean±SD, 0.36±0.28) when compared with stable MCI subjects (0.73±0.32, P<.01) and patients who developed other types of dementia (0.83±0.27, P=.03) (see Figure 2 and Figure 3) . By fixing a cutoff score of 0.6, the sensitivity of APP ratio marker in detecting preclinical AD was 83%, while the specificity was 71%. This study suggested that alteration of platelet APP forms is an early event in AD, antedating clinical symptoms up to at least two years, and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 10 that the measurement of APP ratio may be useful for the identification of preclinical AD in subjects with MCI (Borroni et al., 2003) . This is in line with the general knowledge that biological changes antedate the onset of symptoms in neurodegenerative disorders.
Furthermore, as platelets contain all the enzyme machinery for APP metabolism, it would be hypothesized that ADAM10 and BACE changes may also occur in platelets along with APP form abnormalities. To evaluate this issue, these three parameters were measured in platelets of mild AD patients and controls.
A significant modification of the activity of platelet alpha-secretase (ADAM10) and beta-secretase (BACE) was observed in platelets of AD patients, which paralleled the alteration of APP form ratio since the early stages . Accordingly, the evaluation of the three parameters of platelet machinery, namely APP form ratio, alpha-secretase and beta-secretase, by using artificial neural networks, allowed a very good discrimination of AD in early stages, higher than that obtainable with classical statistical methods (Di Luca et al., 2005) .
Indeed, these results are in accordance with the recent literature suggesting that the combination of different markers may achieve higher accuracy values in early AD.
In this view, the combination of platelet APP ratio along with neuroimaging markers, such as brain perfusion SPECT, increased the discriminative power of the analysis in identifying presymptomatic AD in MCI subjects. The positive predictive value of these combined markers in identifying preclinical AD was 0.87, and the negative predictive value was 0.90 .
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CONCLUSIVE REMARKS
Aging population and increasing life expectancy result in an increasing number of patients with dementia. In the vast majority of individuals symptoms begin after a long period of pre-clinical stage, the so called MCI. Literature data have proposed different biochemical marker strictly associated with the key-players of AD pathogenesis.
Among these, platelet APP form ratio has hold the promises to identify preclinical AD among subjects with MCI with high sensitivity and specificity values, as it detects a fundamental feature of AD neuropathology. Moreover, APP ratio biomarker is reliable, simple to perform as compared to more invasive tests, non invasive and inexpensive.
We acknowledge some limitations which prevent its applicability in the wider field:
APP form ratio should be validated in autopsy-confirmed AD and non-AD cases to further confirm its sensitivity and specificity; further, APP metabolism may be affected by concurrent pharmacological treatments.
The interplay of different markers should be considered for further ameliorating diagnostic accuracy to define MCI subjects who will develop dementia, choosing in each subject which markers are better to perform . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 14 Padovani, A., Borroni, B., Colciaghi, F., et al., 2002 Red line: cut-off value.
